VEGFA and age-related macular degeneration: While providing clinical benefit in the treatment of all angiographic subtypes of neovascular age-related macular degeneration (NV-AMD),23, 24 continuous intravitreous pegaptanib sodium has been shown to have an excellent safety profile over 2 years.23, 25 We now present further data for patients who have continued for 3 years in the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial, showing that no new safety signals have emerged over this additional period.